|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||7.09 - 7.09|
|52-week range||6.39 - 9.25|
|Beta (5Y monthly)||1.09|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Silence Therapeutics plc ( LON:SLN ) shareholders might be concerned after seeing the share price drop 16% in the last...
Joining me today on the call are Mark Rothera, our president and CEO, who will provide an update on the business; Dr. Giles Campion, our head of R&D and chief medical officer, who will provide an update on our clinical programs; and Craig Tooman, our chief financial officer, who will review our financials before opening the call to your questions. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent annual report on file with the SEC.
Image source: The Motley Fool. Silence Therapeutics Plc (NASDAQ: SLN)Q4 2020 Earnings CallMar 30, 2021, 8:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, ladies and gentlemen, and welcome to the Silence Therapeutics full-year 2020 conference call and webcast.